|Description||GSK-J2, a benzazepin derivative, has been found to have poor activity as a JMJD3 inhibitor so that could be used in the biological study of GSK-J1 as a negative control. IC50: > 100 μM.|
|Synonyms||SK-J2; GSK J2; GSKJ2; 1394854-52-4; SCHEMBL15937902; 3705AH|
|Solubility||DMSO: ≥ 42 mg/mL|
|Application||GSK-J2 has been found to have poor activity as a JMJD3 inhibitor so that could be used in the biological study of GSK-J1 as a negative control.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
A novel histone lysine demethylase 4D (KDM4D) inhibitor (IC50= 0.41±0.03 μM)
KDM5-IN-1 is a potent and selective KDM5 inhibitor with modest cell activity (PC9 H3K4Me3 EC50 = 5.2 μM).
CPI 455 is a selective inhibitor of KDM5 demethylases (IC50 value 10 nM for inhibition of full length KDM5A) that specifically alters H3K4 methylation (H3K4me3)...
KDM5-inhibitor is an analog of CPI-455, a selective KDM5 inhibitor. CPI-455 increases levels of H3K4 trimethylation (H3K4me3) and decreases the number of DTPs i...
CBB1003, a piperazine derivative, has been found to be a histone demethylase LSD1 inhibitor that could restrain the proliferation and colony formation of CRC ce...
YUKA1 is a cell-permeable inhibitor of lysine demethylase 5A (KDM5A/RBP2/JARID1A) (IC50 value 2.66 μM). YUKA1 inhibits drug resistance and cancer cell growth in...
GSK-J2, a benzazepin derivative, has been found to have poor activity as a JMJD3 inhibitor so that could be used in the biological study of GSK-J1 as a negative...
NL-103, a nicotinamide derivative, has been found to be an inhibitor of both histone deacetylases and hedgehog pathway. It was found to exhibit activity in decr...